Interpace Diagnostics Enters into Collaborative Agreement with Viatar CTC Solutions to Detect and Characterize Early Cancer in Liquid Biopsies (PDI Inc)
(WorldNews Health)

(Source: PDI Inc) PARSIPPANY, N.J., Feb. 21, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)(`Interpace` or the `Company`), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced the initiation of a collaborative research program with Viatar CTC Solutions Inc. (Viatar), the cancer dialysis company. The collaboration utilizes Viatar`s novel circulating tumor cell collection technology in combination with the Company`s commercialized PancraGENTM assay that is used to help assess indeterminate pancreatic cancer biopsies in patients with pancreatic cysts. Studies are being designed to identify...